<DOC>
	<DOCNO>NCT00385359</DOCNO>
	<brief_summary>Albuterol ( salbutamol ) widely use asthma medication associate undesirable side effect shakiness increase heart rate . Targeted delivery albuterol area lung effect would require low total dose produce beneficial effect reduce side effect . It anticipate 1/13th 1/25th standard nebulized dose albuterol require attain bronchodilator response standard nebulizer treatment determine lung function measurement reduce dose significantly reduce side effect determine hand tremor heart rate .</brief_summary>
	<brief_title>A Pilot Efficacy Study Inhaled Albuterol Delivered With Akita Breath Control</brief_title>
	<detailed_description>Side effect albuterol ( salbutamol ) directly relate dose deliver absorbed blood stream . By control aerosol delivery , dose deliver , site deposition , amount drug absorption determine thus magnitude side effect . Delivery deposition aerosol determine aerosol characteristic ( size timing delivery ) breathing characteristic ( breath size , flow rate breathholding ) . Data support theory high dose albuterol deposit large airway generation prevent enter pulmonary circulation lung periphery , result large magnitude bronchodilator response low circulatory absorbance . This pilot study 10 adult moderate asthma . investigational drug device . It investigation strategy maximize response approve drug minimize side effect . The investigational strategy deposit less 25 % standard nebulized dose airway . This accomplish pair Pari eFlow nebulizer configure deliver particle size 3.5 6 micron , Akita delivery system program deliver drug either late early bolus inspiration . The Akita program specific breathe pattern base participant 's lung function test screen . Moderate asthmatic bronchodilator response &gt; 20 % improvement FEV1 select . Treatments administer separate day 1-7 day apart . Following baseline measurement 1 5 randomize aerosol treatment administer . Efficacy ( FEV1 ) side effect ( tremor heart rate ) monitor 6 hour follow drug administration .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Male female age 1860 year Moderate asthma baseline FEV1 4075 % predict Previous use albuterol ( salbutamol ) At least 20 % improvement FEV1 follow 2.5 mg albuterol ( salbutamol ) deliver nebulizer O2 saturation &gt; 90 % Nonsmoker &gt; 6 month Upper respiratory tract infection asthma exacerbation within 14 day screen Clinically significant abnormal chest radiograph History cardiovascular disorder include coronary insufficiency , cardiac arrhythmia hypertension Unable tolerate bronchodilator withdrawal Known hypersensitivity albuterol ( salbutamol ) Change asthma treatment regimen past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>